Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Benitec BiopharmaBNTC | Open-market buy | 25/12/23–25/12/29 | 25/12/29 | 144,223 sh6 trades | $13.20avg. | $1,903,132.88 | +8.5% | |
Benitec BiopharmaBNTC | Open-market buy | 25/12/18–25/12/22 | 25/12/22 | 46,141 sh6 trades | $11.68avg. | $538,972.28 | +2.6% | |
Benitec BiopharmaBNTC | Open-market buy | 25/11/07 | 25/11/10 | 1,481,481 sh2 trades | $13.50avg. | $19,999,993.5 | +437.9% | |
Benitec BiopharmaBNTC | Open-market buy | 25/03/31 | 25/04/02 | 16,497 sh4 trades | $12.83avg. | $211,736.04 | +1.6% | |
Benitec BiopharmaBNTC | Open-market buy | 25/03/26 | 25/03/28 | 900,000 sh2 trades | $13.00avg. | $11,700,000 | +539.7% | |
Benitec BiopharmaBNTC | Open-market buy | 24/12/23–24/12/24 | 24/12/26 | 47,520 sh4 trades | $11.09avg. | $527,174.46 | +5.2% | |
Benitec BiopharmaBNTC | Open-market buy | 24/12/03 | 24/12/05 | 42,000 sh2 trades | $9.60avg. | $403,200 | +4.6% | |
Benitec BiopharmaBNTC | Open-market buy | 24/11/19–24/11/20 | 24/11/21 | 41,436 sh4 trades | $10.05avg. | $416,615.92 | +4.6% | |
J. Kevin BuchiDirector | Benitec BiopharmaBNTC | Open-market buy | 23/08/11 | 23/08/14 | 51,813 sh | In footnote | No stated value | +18244.0% |
Megan BostonExecutive Director | Benitec BiopharmaBNTC | Open-market buy | 23/08/11 | 23/08/14 | 25,907 sh | In footnote | No stated value | No record |
